Modulari-T Biosciences, a pioneering biotechnology firm focused on regenerative medicine, has officially named Dr. Tanya E. Borsuk as its new Chief Executive Officer. With nearly two decades of extensive experience in biopharma leadership, corporate strategy, and investment, Dr. Borsuk is poised to guide the company through its next growth phase. This strategic appointment underscores Modulari-T's commitment to advancing its innovative therapeutic platform from the laboratory toward clinical application.
A Strategic Leadership Transition
This leadership transition occurs as Modulari-T enters a critical period, preparing to advance its primary programs toward Investigational New Drug (IND) enabling studies. The move allows Dr. Cotnoir-White, a central figure in the company's scientific foundation, to dedicate his focus entirely to platform innovation and scientific vision. This strategic realignment is intended to accelerate the company's progress and foster the expansion of key industry partnerships.
An Accomplished Industry Veteran
Dr. Borsuk is a highly accomplished industry veteran, bringing a unique combination of scientific insight and extensive business development expertise to her new role. Her career is marked by significant achievements, including involvement in over $9 billion worth of business development transactions across North America, Europe, and Asia. She has also played a crucial role in guiding the development and successful launch of nine FDA-approved pharmaceutical products.
Her financial acumen is further demonstrated by her success in helping to raise more than $500 million in venture financing for private biotech enterprises. Before joining Modulari-T, she served as President and CEO of North49 LLC Strategy Consulting, providing expert guidance to biopharma companies. This background provides her with a deep understanding of the strategic needs of a growing biotechnology firm.
Dr. Borsuk's prior executive experience includes serving as Fractional Chief Business Officer at InduPro Therapeutics and Chief Business Officer at Sitryx Therapeutics. She also held prominent positions at Congruence, Flagship Pioneering, and pharmaceutical giants Bristol Myers Squibb and Celgene Corporation. Her history includes structuring major collaborations with industry leaders such as Sanofi, Eli Lilly, and Boehringer Ingelheim.
Driving Future Growth and Innovation
Founded in 2023, Modulari-T is built upon a proprietary second-generation modular immune receptor (MARC) platform and its MoVe delivery system. This innovative technology is designed to harness the power of modular immune receptors to create next-generation therapies. The company's primary focus is on developing groundbreaking treatments within the field of regenerative medicine, targeting previously inaccessible biological pathways.
Dr. Cotnoir-White expressed strong confidence in the new CEO, stating that her leadership will be instrumental in translating the company's scientific breakthroughs into clinical progress. He highlighted the rewarding experience of working with her in a consulting capacity over the past year. Dr. Borsuk reciprocated the enthusiasm, stating she is incredibly excited to lead the team and advance its transformative technology.
The appointment of Dr. Tanya E. Borsuk represents a significant milestone for Modulari-T Biosciences as it pivots towards clinical development and commercialization. Her proven expertise in corporate strategy, financing, and global partnerships provides the company with the leadership needed for its ambitious next phase. This strategic move strongly positions Modulari-T to realize the full potential of its platform and establish itself as a key innovator in regenerative medicine.